Phase 3 Chronic Kidney Disease Trial, Recruiting NCT05457283 Sponsor: Bayer Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT05457283
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be between 1 and 18 years old at the time of signing the consent form
  • You must have previously taken part in the FIONA clinical trial (study 19920) and must not have stopped the treatment early before the end of that trial
  • You must have a confirmed diagnosis of chronic kidney disease (CKD) at a certain level of kidney function (stages 1–3, meaning your kidneys are still working at least partially) at the start of this study
  • You must already be taking a blood pressure medication called an ACE inhibitor or ARB, at the highest dose you can tolerate, and that dose must have stayed the same for at least 30 days before joining
  • Your blood potassium level must be within a safe range — at or below 5.0 mmol/L if you are aged 2 or older, or at or below 5.3 mmol/L if you are under 2 years old, both at the end of the FIONA trial and at the start of this study
  • If you are old enough to legally give consent yourself, you must be able to sign the consent form
  • You must be able to eat or receive nutrition by mouth, bottle, cup, or through a feeding tube (with or without breastfeeding)

Who may not be able to join:

  • You have a planned surgery on the urinary system that is expected to affect how your kidneys work
  • You are scheduled to receive a kidney transplant within the timeframe of this study
  • You have severely high blood pressure (Stage 2) at the start of the study
  • You have dangerously low blood pressure, either with symptoms or measured below a certain level for your age, sex, and height (confirm with trial site)
  • You have a known allergy or sensitivity to the study drug or any of its ingredients
  • You have severe liver disease (for example, a Child-Pugh C score or similar) (confirm with trial site)
  • You are currently taking certain immune-suppressing medications, including rituximab, cyclophosphamide, abatacept, or steroid infusions given through a vein
  • You are currently taking certain other medications that affect the heart, kidneys, or potassium levels, including spironolactone, eplerenone, aliskiren, SGLT2 inhibitors, sacubitril/valsartan, amiloride, or triamterene (confirm with trial site for full list)
  • You are taking both an ACE inhibitor and an ARB at the same time
  • You are taking certain other medications that strongly interact with the way the body processes the study drug (confirm with trial site)
  • You have already been assigned to a treatment in this study before
  • You are currently taking part in another clinical trial involving a treatment or intervention
  • You had a serious side effect related to the study drug during the FIONA trial that caused you to permanently stop taking it
  • You are pregnant, breastfeeding, or planning to become pregnant during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (+)1-888-84 22937

Australian sites

Queensland Children's Hospital, South Brisbane, Queensland
Monash Children's Hospital, Clayton, Victoria
Royal Children's Hospital Melbourne, Parkville, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
8 November 2022
Est. completion
28 November 2028

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇧🇷 Brazil 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇳 India 🇮🇱 Israel 🇮🇹 Italy 🇱🇹 Lithuania 🇲🇾 Malaysia 🇲🇽 Mexico 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland 🇹🇼 Taiwan Turkey (Türkiye) 🇬🇧 United Kingdom 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of participants with treatment emergent adverse event (TEAEs); Change in serum potassium levels from baseline to Day 540±7; Change in systolic blood pressure (SBP) from baseline to Day 540±7

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov